Table 1.
Study characteristics of all patients and long-term survivors
| Descriptive | All patients, n = 161 (%) | Long-term survivors, n = 119 |
|---|---|---|
| Age (median, IQR; years) | 64.5 (57.9–69.9) | 63.7 (57.6–69.9) |
| <65 years | 83 (52 %) | 62 (52 %) |
| ≥65 to 75 years | 78 (48 %) | 57 (48 %) |
| Gender | ||
| Male | 98 (61 %) | 73 (61 %) |
| Female | 63 (39 %) | 46 (39 %) |
| ASA scorea | ||
| I | 92 (57 %) | 71 (61 %) |
| II | 57 (35 %) | 41 (35 %) |
| III | 10 (6 %) | 5 (4 %) |
| > II | 0 | 0 |
| TNM stage | ||
| I | 27 (17 %) | 23 (19 %) |
| II | 84 (52 %) | 70 (59 %) |
| III | 50 (31 %) | 26 (22 %) |
| Location | ||
| Colon | 103 (54 %) | 73 (61 %) |
| Rectum | 58 (36 %) | 46 (39 %) |
| Grade | ||
| High/moderate | 140 (87 %) | 108 (91 %) |
| Low/mucinous | 21 (13 %) | 11 (9 %) |
| T stage | ||
| T1–2 | 33 (20.5 %) | 27 (23 %) |
| T3–4 | 128 (79.5 %) | 92 (77 %) |
| MSI status | ||
| MSI | 36 (22 %) | 25 (21 %) |
| MSS | 125 (78 %) | 94 (79 %) |
| CEA pre-opb | 3.0 (1.0–6.0) | 3.0 (1.0–7.0) |
| ≤4 | 94 (67 %) | 71 (66 %) |
| >4 | 47 (33 %) | 36 (34 %) |
| CEA post-opb | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) |
| ≤4 | 131 (89 %) | 99 (88 %) |
| >4 | 17 (12 %) | 13 (12 %) |
Data are presented as the median with interquartile ranges or numbers with rates (%). Percentages may not add up due to rounding
ASA American Society of Anesthesiology fitness class, MSI microsatellite instability, CEA carcinoembryonic antigen
aData missing from two patients
bBased on patients with available data